For RSV fusion inhibitors, success in “challenge” studies has not translated particularly well to “real-world” studies, where the starting viral loads are higher (due to a longer gap from infection to treatment start). This is the basis for Jay Luly’s running commentary on the deficiencies of the fusion-inhibitor MoA.
Market Data 
Markets 
AI
